Onco Actu du 23 novembre 2018

	3.1 Prévention - Tabac
EU court stands by ban on Swedish tobacco product 'snus' [Reuters] Snus is banned in all EU countries except Sweden, which gained an exemption when joining the bloc in 1995. Swedish Match had challenged the validity of the ban in British courts, arguing that new scientific data had shown it to be less harmful than cigarettes.
	5.1 Traitements - Pré-clinique
Cancer Caveat [Harvard Medical School] At least one epigenetic therapy that had looked promising for lung cancer appears to boost the cancer stem cells that are believed to drive tumors, according to a study published Nov. 19 in Nature Communications. The study also identifies a strategy that reduces these stem cells, curbing lung cancer in mice.
	5.12.8 Immunothérapies - Economie
Immunotherapy drug made available for some NHS patients with lung cancer [Cancer Research UK] The Cancer Drugs Fund allows patients to access treatments before they are fully approved for use in the NHS. This gives the NHS and the drug company time to collect more data on the long-term benefits of the drug. The company has also agreed a discounted price.
Cancer Drugs Fund to offer MSD's Keytruda for lung cancer [Pharmafile] NICE said that further data would be necessary to determine whether the drug was cost-effective enough to be used routinely on the NHS. MSD will continue to gather efficacy data for Keytruda until June 2019, under a CDF managed access agreement, at which time the case will be reviewed again.
New life-extending lung cancer treatment approved by NICE [NICE] NICE today recommends in draft guidance that immunotherapy drug pembrolizumab (also known as Keytruda), used with pemetrexed and platinum chemotherapy, should be a treatment option for people with untreated advanced lung cancer. NICE estimates that more than 3,000 patients in England may be eligible for this combination treatment.
	6.6 Publications
Do we need an Open Science coalition? [LSE Impact Blog] Open Science is a strange concept. Depending on who you speak to, it can be a set of scientific practices, a social justice issue, a complete fad, part of a political capitalist regime, or just a different but undefinable form of traditional science.
AI peer reviewers unleashed to ease publishing grind [Nature] A suite of automated tools is now available to assist with peer review but humans are still in the driver's seat.